JAK inhibitors vs standard therapy for lung scarring in Anti-Synthetase Syndrome
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have been diagnosed with Anti-Synthetase Syndrome (an autoimmune disease that affects the lungs and muscles).
- You have a type of lung scarring called interstitial lung disease (ILD) confirmed by a special CT scan.
- Your lung disease is active enough that you need to start or increase immune-suppressing therapy, but you have never taken steroids, immune-suppressants, or biologics for it before.
- You are not pregnant, breastfeeding, free of severe infections, cancer, or major organ failure, and have no known allergies to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injected medication (Genakumab) for people with connective tissue disease-related lung scarring. It aims to see if it helps stabilize or improve lung function safely.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study compares two treatment approaches for rheumatoid arthritis (RA): newer drugs called JAK inhibitors and traditional treatments. It aims to see which is more effective at reducing symptoms and improving daily life.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This study compares different treatment strategies for people with rheumatoid arthritis who also have interstitial lung disease (a type of lung scarring). It aims to find the best way to manage both conditions and potentially slow lung damage.
Hear when a new Antisynthetase Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.